Investors Overview


MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. “Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio® brand; and Skin family with AlloBurn™ brand. AmnioFix, EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a unique bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

ExchangeNASDAQ CM (US Dollar)
Change Stock is Up 0.07 (0.49%)

05/22/17  4:00 p.m. ET

Minimum 20 minute delay

Stock chart for: MDXG.O.  Currently trading at $14.33 with a 52 week high of $15.40 and a 52 week low of $6.90.
Data Provided by Thomson Reuters


View All
MiMedx To Attend The 14th Annual Craig-Hallum Institutional Investor ConferenceMARIETTA, Ga., May 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placent

Read More

MiMedx Receives Innovative Technology Supplier of the Year Award from Vizient, Inc.The largest member-Driven Health Care Performance Improvement Company recognizes MiMedx for its positive impact on patient care MARIETTA, Ga., May 1, 2017 /PRNewswire/ -- MiMedx Group,

Read More

MiMedx Announces Record Results For First Quarter Of 2017Company records 36% revenue growth, 261% increase in Net Income and 51% increase in Adjusted Net Income* over Q1 2016 MARIETTA, Ga., April 28, 2017 /PRNewswire/ -- MiMedx Group, Inc. (N

Read More


Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever MIMEDX GROUP INC posts new information to the site. Just enter your e-mail address and click Submit.